Aeglea Bio Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $27.32 million
- Book Value:
- Revenue TTM:
- $2.33 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Aeglea Bio Therapeutics Inc had its IPO on 2016-04-07 under the ticker symbol AGLE.
The company operates in the Healthcare sector and Biotechnology industry. Aeglea Bio Therapeutics Inc has a staff strength of 0 employees.
Shares of Aeglea Bio Therapeutics Inc opened at $0.31 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $0.29 - $0.31, and closed at $0.29.
This is a -3.13% slip from the previous day's closing price.
A total volume of 214,783 shares were traded at the close of the day’s session.
In the last one week, shares of Aeglea Bio Therapeutics Inc have slipped by -12.47%.
Aeglea Bio Therapeutics Inc's Key Ratios
Aeglea Bio Therapeutics Inc has a market cap of $27.32 million, indicating a price to book ratio of 0.3508 and a price to sales ratio of 4.0838.
In the last 12-months Aeglea Bio Therapeutics Inc’s revenue was $2.33 million with a gross profit of $-262000 and an EBITDA of $-83214000. The EBITDA ratio measures Aeglea Bio Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Aeglea Bio Therapeutics Inc’s operating margin was -3640.23% while its return on assets stood at -58.53% with a return of equity of -124.87%.
In Q4, Aeglea Bio Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 95.4%.
Aeglea Bio Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aeglea Bio Therapeutics Inc’s profitability.
Aeglea Bio Therapeutics Inc stock is trading at a EV to sales ratio of 1.2651 and a EV to EBITDA ratio of 0.5355. Its price to sales ratio in the trailing 12-months stood at 4.0838.
Aeglea Bio Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $71.14 million
- Total Liabilities
- $14.66 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Aeglea Bio Therapeutics Inc ended 2023 with $71.14 million in total assets and $0 in total liabilities. Its intangible assets were valued at $71.14 million while shareholder equity stood at $50.31 million.
Aeglea Bio Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $14.66 million in other current liabilities, 6000.00 in common stock, $-425624000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $34.86 million and cash and short-term investments were $55.71 million. The company’s total short-term debt was $625,000 while long-term debt stood at $0.
Aeglea Bio Therapeutics Inc’s total current assets stands at $62.26 million while long-term investments were $0 and short-term investments were $20.85 million. Its net receivables were $0 compared to accounts payable of $677000.00 and inventory worth $0.
In 2023, Aeglea Bio Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Aeglea Bio Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Aeglea Bio Therapeutics Inc stock is currently trading at $0.29 per share. It touched a 52-week high of $3.17 and a 52-week low of $3.17. Analysts tracking the stock have a 12-month average target price of $2.75.
Its 50-day moving average was $0.43 and 200-day moving average was $0.56 The short ratio stood at 2.04 indicating a short percent outstanding of 0%.
Around 186% of the company’s stock are held by insiders while 7087.2% are held by institutions.
Frequently Asked Questions About Aeglea Bio Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company’s lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company’s preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.